Author/Authors :
Tsang، نويسنده , , Teresa S.M and Barnes، نويسنده , , Marion E. and Abhayaratna، نويسنده , , Walter P. and Cha، نويسنده , , Steven S. and Gersh، نويسنده , , Bernard J. and Langins، نويسنده , , Andrew P. and Green، نويسنده , , Tammy D. and Bailey، نويسنده , , Kent R. and Miyasaka، نويسنده , , Yoko and Seward، نويسنده , , James B.، نويسنده ,
Abstract :
Left atrial (LA) enlargement, left ventricular (LV) diastolic dysfunction, and increased arterial stiffness are all associated with adverse cardiovascular outcomes. The rate, magnitude, and concordance of modifiability of these risk markers have not been well characterized. Twenty-one patients (mean age 69 ± 8 years; 52% women) with isolated diastolic dysfunction and indexed LA volumes ≥32 ml/m2 were randomly assigned to receive either quinapril at a target dose of 60 mg/day or matching placebo for 12 months. Echocardiographic maximum LA volume and LV diastolic function and arterial stiffness by the augmentation index were measured at baseline and 6 and 12 months. Analysis was based on intention to treat. Baseline characteristics were comparable between the treatment (n = 9) and placebo (n = 12) groups. The mean reduction in LA volume of 4.2 ± 7.8 ml/m2 in the quinapril group was significant (p = 0.01) compared with the increase in LA volume in the placebo group (5.5 ± 8.1 ml/m2). This represents a relative improvement of 9.7 ml/m2. Change in LV filling pressure in terms of E/e′ and diastolic function grade did not reach significance. A reduction in the augmentation index was associated with a decrease in indexed LA volume (odds ratio 11, p = 0.046), independent of changes in systolic blood pressure. In conclusion, LA structural remodeling appeared reversible with quinapril, which occurred in parallel with an improvement in arterial stiffness but independent of blood pressure changes.
